Carregant...
Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells
Blasts from different patients with acute myeloid leukemia (AML) vary in the agent(s) to which they are most responsive. With a myriad of novel agents to evaluate, there is a lack of predictive biomarkers to precisely assign targeted therapies to individual patients. Primary AML cells often survive...
Guardat en:
| Publicat a: | PLoS One |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5933738/ https://ncbi.nlm.nih.gov/pubmed/29723246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0196805 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|